ANI Pharmaceuticals, Inc. (ANIP): Price and Financial Metrics

ANI Pharmaceuticals, Inc. (ANIP): $31.00

0.48 (+1.57%)

POWR Rating

Component Grades













Add ANIP to Watchlist
Sign Up

Industry: Biotech



in industry


  • ANIP scores best on the Growth dimension, with a Growth rank ahead of 72.5% of US stocks.
  • The strongest trend for ANIP is in Momentum, which has been heading down over the past 179 days.
  • ANIP's current lowest rank is in the Quality metric (where it is better than 4.36% of US stocks).

ANIP Stock Summary

  • Price to trailing twelve month operating cash flow for ANIP is currently 150.1, higher than 96.91% of US stocks with positive operating cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Ani Pharmaceuticals Inc is reporting a growth rate of 167.33%; that's higher than 87.98% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ANIP comes in at -35.13% -- higher than that of only 11.48% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ani Pharmaceuticals Inc are DRQ, IDXG, WLL, BCOR, and ADMA.
  • ANIP's SEC filings can be seen here. And to visit Ani Pharmaceuticals Inc's official web site, go to

ANIP Valuation Summary

  • In comparison to the median Healthcare stock, ANIP's EV/EBIT ratio is 285.67% lower, now standing at -54.4.
  • Over the past 243 months, ANIP's price/sales ratio has gone NA NA.
  • ANIP's price/earnings ratio has moved down 8.8 over the prior 243 months.

Below are key valuation metrics over time for ANIP.

Stock Date P/S P/B P/E EV/EBIT
ANIP 2021-08-31 1.8 2.0 -22.5 -54.4
ANIP 2021-08-30 1.6 1.8 -20.3 -50.8
ANIP 2021-08-27 1.7 1.9 -20.7 -51.4
ANIP 2021-08-26 1.6 1.8 -20.4 -50.9
ANIP 2021-08-25 1.7 1.9 -20.8 -51.6
ANIP 2021-08-24 1.7 1.9 -21.5 -52.7

ANIP Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -67.31%.
  • The 5 year price growth rate now stands at -27.02%.
  • Its 5 year net cashflow from operations growth rate is now at 21.9%.
Over the past 49 months, ANIP's revenue has gone up $44,698,000.

The table below shows ANIP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 212.459 9.798 -22.102
2021-06-30 213.377 13.586 -17.221
2021-03-31 213.222 34.225 -15.451
2020-12-31 208.475 15.267 -22.548
2020-09-30 199.189 25.779 -23.748
2020-06-30 197.547 49.186 -20.287

ANIP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANIP has a Quality Grade of D, ranking ahead of 9.89% of graded US stocks.
  • ANIP's asset turnover comes in at 0.453 -- ranking 96th of 682 Pharmaceutical Products stocks.
  • NWBO, CYTR, and NAII are the stocks whose asset turnover ratios are most correlated with ANIP.

The table below shows ANIP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.453 0.570 -0.047
2021-06-30 0.457 0.592 -0.029
2021-03-31 0.460 0.600 -0.018
2020-12-31 0.446 0.582 -0.047
2020-09-30 0.427 0.596 -0.063
2020-06-30 0.425 0.619 -0.054

ANIP Price Target

For more insight on analysts targets of ANIP, see our ANIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.00 Average Broker Recommendation 1.75 (Moderate Buy)

ANIP Stock Price Chart Interactive Chart >

Price chart for ANIP

ANIP Price/Volume Stats

Current price $31.00 52-week high $60.23
Prev. close $30.52 52-week low $22.73
Day low $30.54 Volume 67,100
Day high $31.20 Avg. volume 125,157
50-day MA $29.29 Dividend yield N/A
200-day MA $36.23 Market Cap 535.43M

ANI Pharmaceuticals, Inc. (ANIP) Company Bio

ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company was founded in 2004 and is based in Baudette, Minnesota.

ANIP Latest News Stream

Event/Time News Detail
Loading, please wait...

ANIP Latest Social Stream

Loading social stream, please wait...

View Full ANIP Social Stream

Latest ANIP News From Around the Web

Below are the latest news stories about Ani Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANIP as an investment opportunity.

ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team

BAUDETTE, Minn., February 24, 2022--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced two additions to its Rare Disease Business Unit leadership team. Mary Pao, M.D., Ph.D., has been appointed Chief Medical Officer, and Elizabeth Powell, J.D., has been appointed Chief Compliance Officer and Head of Legal. These appointments build on the roster of industry experts comprising the ANI Rare Disease Business Unit executive team.

Yahoo | February 24, 2022

BioMarin Pharmaceutical (BMRN) Q4 Earnings and Revenues Top Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity

Oakrum Pharma, LLC ("Oakrum Pharma"), in collaboration with ANI Pharmaceuticals (NASDAQ: ANIP), announce that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for a generic version of Cystadane®1 (betaine anhydrous for oral solution) Powder in a 180 gm bottle and granted Competitive Generic Therapy (CGT) of 180 days of exclusivity. Shipments of the generic product began in early February, 2022.

Yahoo | February 14, 2022

ANI Pharmaceuticals: Back In The Buy Zone

No summary available.

Seeking Alpha | February 8, 2022

High Note Wealth, LLC Buys The Walt Disney Co, Uber Technologies Inc, Block Inc, Sells ...

Investment company High Note Wealth, LLC (Current Portfolio) buys The Walt Disney Co, Uber Technologies Inc, Block Inc, VanEck Investment Grade Floating Rate ETF, iShares iBoxx $ High Yield ex Oil & Gas Corporate, sells AdvisorShares Pure US Cannabis ETF, Biogen Inc, Citrix Systems Inc, , Intel Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, High Note Wealth, LLC.

Yahoo | February 1, 2022

Read More 'ANIP' Stories Here

ANIP Price Returns

1-mo 3.30%
3-mo -17.27%
6-mo -26.07%
1-year -9.75%
3-year -54.40%
5-year -32.56%
YTD -32.73%
2021 58.68%
2020 -52.91%
2019 36.98%
2018 -30.15%
2017 6.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5819 seconds.